Современная онкология (Dec 2013)

The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer

  • M V Cherkasova,
  • S V Khokhlova,
  • S V Limareva,
  • I Y Bazaeva,
  • N F Orel,
  • V A Gorbunova,
  • I V Poddubnaya

Journal volume & issue
Vol. 15, no. 4
pp. 14 – 18

Abstract

Read online

Given the high rate of recurrence of epithelial ovarian cancer after radical treatment is necessary to improve the therapeutic approach to its treatment. New drug of marine origin trabectedin has shown high efficacy in monotherapy and in combination with different cytostatics in the treatment of platinum-sensitive recurrent of ovarian cancer. A randomized trial OVA-301 showed the greatest benefit of a combination of trabectedin with pegylated liposomal doxorubicin in the subgroup of patients with partially platinum-sensitive recurrent of ovarian cancer. Acceptable toxicity profile of the drug, presented mainly neutropenia and transient increase of transaminases, making it promising for further study.

Keywords